Floatz logo

scg101

Hepatitis B Virus Related Hepatocellular Carcinoma

SCG Cell Therapy Pte. Ltd.Cell therapyPhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

520 Active assets in the Hepatitis B Virus Related Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Huaier Granule
Tongji Hospital
Phase 4BBB
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB
Carboplatin
AstraZeneca
Phase 4BB

View all 50 →

Same molecule, other indications

scg101 is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →